Prefer Hikal, Lupin: Aashish Tater

Aashish Tater of fortunewizard.com told CNBC-TV18, "In Dr Reddy's Laboratories after that first alert only we suggested a switch from it to something very interesting story going forward which is Hikal Limited. We feel Dr Reddy will still be in pain and there will be further EPS downgrades because the surprise on negative side never stops on the first alert itself. We have seen what has happened to other pharmaceutical names.""On other hand Hikal we feel has got a huge transformation that is going to take place over years. So, we feel that will be a multi-bagger from current levels and people who are looking for safety net in the space, can either go for Lupin or for Hikal," he added.